GlassScriptPhysician profile
Shannon Long
NPI 1306259916
$2,339.33
in general payments reported to CMS, 2019-2025
26 companies · $1,209 in 2025
The $1,209 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,131 · 2025: $1,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,339.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $386.72 | 2024-2025 | |
| Lilly USA, LLC | $247.18 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $219.22 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $151.33 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $148.30 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Insulet Corporation | $146.68 | 2024-2025 | Omnipod |
| Amgen INC. | $145.03 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Sanofi-Aventis U.S. LLC | $96.57 | 2024-2025 | |
| Abbvie INC. | $92.48 | 2024-2025 | |
| Daiichi Sankyo INC. | $80.31 | 2024-2025 | Injectafer |
| Dexcom, INC. | $75.44 | 2024 | Dexcom G6 Transmitter |
| Philips North America LLC | $60.52 | 2024 | (K95) Ecc Solutions, (Cl3) Cardiac, (Ck7) Extended Holter |
| Bayer Healthcare Pharmaceuticals INC. | $55.38 | 2024-2025 | |
| Axsome Therapeutics, INC. | $54.97 | 2024-2025 | Auvelity |
| Sumitomo Pharma America, INC. | $53.63 | 2025 | Gemtesa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $51.90 | 2024-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.71 | 2025 | Jardiance |
| Abbott Laboratories | $41.70 | 2025 | Eterna, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $31.42 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astrazeneca Pharmaceuticals LP | $31.24 | 2024-2025 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.94 | 2025 | Xifaxan |
| Dynavax Technologies Corporation | $22.10 | 2024 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $21.54 | 2025 | Rexulti |
| Edwards Lifesciences Corporation | $20.49 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $17.77 | 2024 | Intellis Adaptivestim |
| Tonix Medicines, INC. | $13.76 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.